Firefly and NeuroSigma Partner to Bring Non-Drug ADHD Device to More Clinicians

Key Points

• Firefly Neuroscience will introduce NeuroSigma’s Monarch eTNS System to its nationwide network of clinicians who use the Evoke platform.
• Monarch is an FDA-cleared, prescription-only, non-drug ADHD treatment for children ages 7 through 12 who are not taking prescription ADHD medication.
• Firefly will support clinician education; NeuroSigma will provide training, prescribing support and product fulfillment.
• Firefly’s research into EEG-based ADHD biomarkers remains subject to further study and validation.

Firefly Neuroscience (NASDAQ: AIFF) and NeuroSigma have formed a partnership aimed at expanding clinician awareness of NeuroSigma’s Monarch eTNS System, an at-home treatment option for eligible children with ADHD. Firefly will introduce the device to psychiatry, neurology and behavioral health practices that use its Evoke brain-function assessment platform.

Monarch Offers an At-Home ADHD Treatment Option

The prescription-only Monarch device delivers mild external trigeminal nerve stimulation through an adhesive patch placed on a child’s forehead during sleep. It is FDA-cleared as a stand-alone treatment for children ages 7 through 12 with ADHD who are not currently taking prescription ADHD medication.

NeuroSigma began U.S. sales of its second-generation device in July 2026. The company said it had developed a waitlist of more than 1,500 patients, caregivers and healthcare providers before launch and expanded payment options in September.

Firefly Will Introduce Monarch to Evoke Clinicians

Under the agreement, Firefly will present Monarch to its Evoke clinician customers and help educate them about the treatment. NeuroSigma will handle clinical training, prescribing support and fulfillment through its specialty pharmacy partner.

Evoke combines EEG and event-related potential testing with AI-powered analysis to provide information about brain function and help clinicians track changes over time. Firefly said the partnership connects practices using that measurement platform with an additional treatment option for eligible children; the announcement does not say Evoke is required to prescribe Monarch.

ADHD Biomarker Research Remains Early Stage

Firefly also cited research announced in March 2026 into EEG-based patterns that may help distinguish among three ADHD presentations. The company said those findings need further research and validation before they could be used to help match patients with treatments or monitor responses.

Investor Takeaway: Distribution Opportunity, but Economics Are Unclear

For Firefly investors, the partnership gives the company another way to engage its Evoke clinician network and may help strengthen relationships with practices focused on pediatric ADHD. The announcement, however, does not disclose payment terms, revenue-sharing arrangements or expected sales, so its financial impact on AIFF cannot yet be assessed.

The clearest measures of progress will be whether clinicians adopt the offering and whether the partnership produces revenue for Firefly. NeuroSigma’s reported waitlist signals interest in Monarch, but it does not establish how many patients will receive the device through Firefly’s network.

Image disclaimer: The device shown is for illustrative purposes only and is not the actual device.